STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page number
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the	1-4
		abstract	
		(b) Provide in the abstract an informative and balanced summary of what was	1-4
		done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4,5
Objectives	3	State specific objectives, including any prespecified hypotheses	4,5
Methods			
Study design	4	Present key elements of study design early in the paper	5-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of	
Setting	J	recruitment, exposure, follow-up, and data collection	5-8
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of	
Tanvo, pana	O	selection of participants. Describe methods of follow-up	5-8
		Case-control study—Give the eligibility criteria, and the sources and methods	
		of case ascertainment and control selection. Give the rationale for the choice of	
		cases and controls	
		Cross-sectional study—Give the eligibility criteria, and the sources and	
		methods of selection of participants	
		(b) Cohort study—For matched studies, give matching criteria and number of	
		exposed and unexposed	
		Case-control study—For matched studies, give matching criteria and the	
		number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and	
Variables	,	effect modifiers. Give diagnostic criteria, if applicable	5-8
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	
measurement	O	assessment (measurement). Describe comparability of assessment methods if	5-8
measurement		there is more than one group	5-6
Bias	9	Describe any efforts to address potential sources of bias	5-8
Study size	10	Explain how the study size was arrived at	- 5 -8 —
Quantitative variables	11	Explain how due study size was arrived at: Explain how quantitative variables were handled in the analyses. If applicable,	
	11	describe which groupings were chosen and why	5-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for	
	12	confounding	5-8
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed	
		Case-control study—If applicable, explain how matching of cases and controls	
		was addressed	
		Cross-sectional study—If applicable, describe analytical methods taking	
		account of sampling strategy	
		(g) Describe any sensitivity analyses	
		(E) Describe any sensitivity analyses	

Results				
Participants 13		(a) Report numbers of individuals at each stage of study—eg numbers potentially eligi examined for eligibility, confirmed eligible, included in the study, completing follow-t and analysed		
		(b) Give reasons for non-participation at each stage		
		(c) Consider use of a flow diagram		
Descriptive	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and		
data		information on exposures and potential confounders	8-11	
		(b) Indicate number of participants with missing data for each variable of interest		
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)		
Outcome data 1.	15*	Cohort study—Report numbers of outcome events or summary measures over time		
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	f	
		Cross-sectional study—Report numbers of outcome events or summary measures		
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their		
		precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	•	
		(b) Report category boundaries when continuous variables were categorized		
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period		
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses		
Discussion				
Key results	18	Summarise key results with reference to study objectives	11-14	
•	19	Discuss limitations of the study, taking into account sources of potential bias or		
		imprecision. Discuss both direction and magnitude of any potential bias	11-14	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,		
		multiplicity of analyses, results from similar studies, and other relevant evidence	11-14	
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-14	
Other informati	on			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	NA	

^{*}Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.